作者
Boon H Chua, Emma K Link, Ian H Kunkler, Timothy J Whelan, A Helen Westenberg, Guenther Gruber, Guy Bryant, Verity Ahern, Kash Purohit, Peter H Graham, Mohamed Akra, Orla McArdle, Peter O'Brien, Jennifer A Harvey, Carine Kirkove, John H Maduro, Ian D Campbell, Geoff P Delaney, Joseph D Martin, T Trinh T Vu, Thierry M Muanza, Anthony Neal, Ivo A Olivotto
发表日期
2022/8/6
期刊
The Lancet
卷号
400
期号
10350
页码范围
431-440
出版商
Elsevier
简介
Background
Whole breast irradiation (WBI) after conservative surgery for ductal carcinoma in situ (DCIS) reduces local recurrence. We investigated whether a tumour bed boost after WBI improved outcomes, and examined radiation dose fractionation sensitivity for non-low-risk DCIS.
Methods
The study was an international, randomised, unmasked, phase 3 trial involving 136 participating centres of six clinical trials organisations in 11 countries (Australia, New Zealand, Singapore, Canada, the Netherlands, Belgium, France, Switzerland, Italy, Ireland, and the UK). Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins. They were assigned to one of four groups (1:1:1:1) of no tumour bed boost versus boost after conventional versus hypofractionated WBI, or randomly assigned …
学术搜索中的文章
BH Chua, EK Link, IH Kunkler, TJ Whelan… - The Lancet, 2022